Although inhibition of programmed death-1 (PD1) or programmed cell death ligand 1 (PD-L1) therapies have had limited success in treating colorectal cancer, immunotherapy is now being used as second-line treatment for patients with dMMR/MSH-H (approximately 15% of patients with colorectal cancer) (5, 6). This evidence concerns the gene CD274 and colorectal cancer.